Correction: Safety and efficacy of lapatinib

Correction: Safety and efficacy of lapatinib, binimetinib, and vinorelbine for RAS mutant metastatic colorectal cancer: results of the RASTRIC Phase I/II trial. Download PDF The Original Article was published on 07 April 2026 Explore related subjects Discover the latest articles and news in related subjects. Chemotherapy Colorectal cancer Phase I trials Phase II trials Targeted therapies Correction to: British Journal of Cancer https://doi.org/10.1038/s41416-026-03398-x, article published online 07 April 2026 Following publication, minor discrepancies were identified between the data presented in the article body and associated Figures.

In the Abstract, RESULTS section, the article originally stated “…with 9 (27%) achieving stable disease”; the correct statement is: “…with 8 (24%) achieving stable disease”. In the Results section, the article originally stated “…nine patients had stable disease at first evaluation (27%)”; the correct statement is: “…eight patients had stable disease at first evaluation (24%)”. In the Discussion section, the article originally stated: “…although 23% achieved stable disease with three maintaining stability beyond three months”; the correct statement is: “…although 20% achieved stable disease with three maintaining stability beyond three months.” The original article has been corrected.

Author information Authors and Affiliations Department of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands Maarten A. Roodhart Center for Molecular Medicine, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands Maarten A. Snippert Oncode Institute, Utrecht, the Netherlands Maarten A.

Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult with qualified healthcare professionals for medical decisions and treatment options.